Complex Innovative Design
Decentralized Clinical Trials
European Medicines Agency
Hybrid Clinical Trials
In-Vitro Diagnostic Regulation
Outsourcing Clinical Trials
Real-World Evidence (RWE)
Research & Development
Research and Development
Robotic-Assisted Surgery (RAS)
RWE Decision Alert
Everything You Need to Know About Market Access in China
Our market access experts have outlined the healthcare system and key market access pathways that are opening in China for pharmaceutical products, including vaccines.
Improving Access to Medicine: The Role of Pharma Companies in Emerging Markets
Our Market Access experts have identified risks and opportunities associated with improving access to medicines in emerging countries.
Pricing and Reimbursement of Oncological Medicines in Spain
Discover how companies’ target prices are impacted by the different variables leveraged during the P&R process for oncology and oncohematology’s first indication.
Next Generation Therapies: Access, Pricing and Ethical Issues in Perspective
In this white paper, we will explore wide range of new therapies we term “Next Generation Therapies” and challenges related to them.
Real-World Evidence: Five Facts You Need to Know
Learn more about RWD and its future challenges for Europe, we asked Romain Finas, Vice President of Real-World Evidence (RWE) at Alira Health, to share five facts that you need to know about it.
Early Access Programs: Keys to Success
Discover Alira Health’s top five recommendations to building a successful Early Access Programs (EAP).
Fostering Innovation and the Importance of Market Access
Interview with Robert Fabregat, CEO of Biocat, and Chus Castillo, Director of Global Market Access at Alira Health, to understand how companies can foster innovation locally and globally,(...)
Enhancing Patient Access with Early Access Programs
Download this white paper to discover Early Access Programs' benefits, related challenges, and ways to overcome them.
Alira Health Published in Business Development & Licensing Journal
Experts from the Alira Health team recently shared their thoughts regarding the importance of market access insights for the success of licensing operations with professionals from(...)
Economics and Value Proposition for Medical Device in the U.S.
A health economics evaluation assists companies during product development to better understand the product's impact across the ecosystem and position it appropriately.
Critical Success Factors in Market Access
Today’s MedTech market is more concentrated than ever, with critical factors that need to be examined to advance a new product.
WHO Guideline: Recommendations on Pharma Pricing Policies
Alira Health’s market access experts dive into the WHO recommendations and provide advice on how companies can brace for impact.
Our Parallel Trade Expertise
Alira Health is proud to announce our new collaboration with Mark Inigo Jones, an industry leader in European parallel trade of pharmaceutical products.
Assessment of POCT Device Potential and Definition of a Go -To- Market Strategy for Selected Countries in South America
When our client, an Asia-based medtech company with a novel POCT solution, wanted to understand the best market access strategy to enter into Latin America, Alira Health shed light(...)
Latest from Alira Health
The 2024 Global Medtech Contract Manufacturing Report: Executive Summary
The Importance of Involving Patients in the Health Technology Assessment Process for Rare Diseases
Experts Annabel de Maria and Ahmad Bechara share how engaging rare disease patients in the HTA process gives them the opportunity to have a meaningful impact.
Biopharma in 2024: The Industry Outlook
Insights from recent J.P. Morgan Healthcare Conference including what's changed in biopharma since last year and what to expect this year.
Pharma Company Succeeds in Adding Medicine to World Health Organization Essential Medicines List
A pharma company with a blood disorder treatment needed support to submit a value dossier to the WHO to add a medicine to the Essential Medicines List.
Pharma Company Extends to New Markets through Strategic Licensing Agreements
A Swedish pharma company saw a market opportunity to expand access to its proprietary product outside of the Nordics and sought support developing strategic licensing deals.
Pharma Develops e-Health Solution That Prioritizes Patients’ True Unmet Needs
A leading pharma company in the respiratory market sought support developing the right digital platform to expand their patient base and increase retention.
Connect with our biotech experts onsite in Barcelona at Bio-Europe Spring. How can we support your development plan and funding path?
XXII Conferenza Nazionale Sulla Farmaceutica
Meet Giovanni Firenze, Partner Consulting Italy, onsite in Catania and learn more about the impact of the new AIFA reform.
World EPA Congress Europe
Look for market access and pricing experts Ahmad Bechara and Andrea Mantovani representing Alira Health on the agenda at World EPA Congress.
Robotic-assisted Surgery in Orthopedic Procedures: Current Landscape and 2024 Outlook
What Comes After the mRNA Vaccines?
In the third episode of VacciTalks, we’ll discuss these new alternatives to mRNA vaccines and the promise they hold.
Medtech CDMO: Market and M&A Global Trends in 2024
This webinar replay investigates the current state of the global medtech CDMO industry and highlight Europe as a promising frontier for consolidation.
Alira Health Releases The 2024 Global Medtech Contract Manufacturing Report
Alira Health announced the release of the 2024 Global Medtech Contract Manufacturing Report. This report offers a comprehensive analysis of trends in the global medtech contract manufacturing(...)
Alira Health Advises Aesculapius Farmaceutici Srl in Its Acquisition by Ceres Pharma NV
We are pleased to have represented as transaction advisor Aesculapius, a leading Italian pharmaceutical company active in the development and distribution of prescription drugs, OTC(...)
Alira Health Releases Global Report on Robotic-Assisted Surgery (RAS) in Orthopedic Procedures
New analysis reveals the RAS in Orthopedics market is anticipated to grow 10% annually over the next five years, reaching more than 2.5 million procedures in the EU, UK and US.
Best Practices for Health Technology Assessment of Robotic Assisted Surgery
An expert panel developed seven best-practice recommendations for evaluating Robotics Assisted Surgical systems and here are the results.
Therapeutic IgG-Like Bispecific Antibodies: Modular Versatility and Manufacturing Challenges
Our experts conducted a deep evaluation of IgG-like bsAbs including general advantages and disadvantages compared with MAbs and more.
Immunoglobulin Fc-Fusion Proteins
Our experts published a series of articles in BioProcess International reviewing the state of the art of Fc – fusion proteins, including their structure and molecular design, manufacturing(...)